SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics submitted a formal dispute resolution request to…

Outlook Therapeutics, Inc. · 8-K filed Apr 7, 2026 at 16:15 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Apr 7, 2026 at 16:15 ET

Outlook Therapeutics submitted a formal dispute resolution request to the FDA regarding a Complete Response Letter for its ONS-5010/LYTENAVA biologics license application, and the FDA has accepted the request and granted a meeting with the deciding official. This is a procedural step in the regulatory review process for a drug that was previously not approved.

  • Company submitted a Formal Dispute Resolution Request (FDRR) to the FDA regarding a December 30, 2025 Complete Response Letter (CRL) for ONS-5010/LYTENAVA
  • FDA accepted the FDRR and granted a meeting with the deciding official to be conducted in April 2026
  • The BLA concerns ONS-5010/LYTENAVA for treatment of neovascular age-related macular degeneration
  • Company believes existing clinical data from NORSE TWO and NORSE EIGHT trials support approval

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access